<div id="readability-page-1"><h3>Claim 30% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>BeOne Medicines Ltd ( (HK:6160) ) has provided an announcement. BeOne Medicines Ltd. has nominated ten directors for election at its 2026 annual general meeting, including three new candidates: Dr. Felix J. Baker as a non-executive director, and Elizabeth F. Mooney and Dr. Charles L. Sawyers as independent non-executive directors, each to serve until the 2027 meeting if elected. The company states that the new independent nominees meet Hong Kong listing independence criteria and that further details will be circulated to shareholders ahead of the meeting. Four current independent non-executive directors, Michael Goller, Ranjeev Krishana, Dr. Corazon D. Sanders and Qingqing Yi, will retire at the 2026 AGM to focus on other commitments, with the company emphasizing there are no disagreements behind their departure. Conditional on shareholder approval, BeOne will also reconstitute its audit and compensation committees, appointing Ms. Mooney and Ms. Sharp to key roles, signaling a refreshed governance structure that may influence oversight of financial reporting and executive pay. The most recent analyst rating on (HK:6160) stock is a Buy with a HK$290.00 price target. To see the full list of analyst forecasts on BeOne Medicines Ltd stock, see the HK:6160 Stock Forecast page. More about BeOne Medicines Ltd BeOne Medicines Ltd., incorporated in Switzerland and listed in Hong Kong, operates in the biopharmaceutical sector, focusing on the development of innovative medicines. The company is governed by a board comprising executive, non-executive and independent non-executive directors, supported by specialized committees overseeing audit, compensation and corporate governance matters. Average Trading Volume: 3,702,009 Technical Sentiment Signal: Buy Current Market Cap: HK$283.9B Learn more about 6160 stock on TipRanks’ Stock Analysis page.</div>

06160

688235

BeOne Medicines Ltd has announced the nomination of ten directors for election at its 2026 AGM, including three new candidates. Four current independent directors will retire, with no disagreements cited. The company plans to reconstitute its audit and compensation committees, indicating a refreshed governance structure. The latest analyst rating for BeOne Medicines Ltd (HK:6160) is a Buy with a price target of HK$290.00. BeOne operates in the biopharmaceutical sector, focusing on innovative medicines and is listed in Hong Kong.

BeOne Medicines Revamps Board and Committees Ahead of 2026 AGM